Therapies
As a result of its solid and successful experience as partner with the Italian Health System, its significant expansion into international operations and a fundamental commitment to research and development, Kedrion’s line of plasma-derived products is broad and diverse.
With treatments for many rare and debilitating diseases and conditions from hemolytic disease in newborns to immune deficiencies to hemophilia, Kedrion offers a wide and expanding array of treatments and therapies.
Product Portfolio
RARE DISEASES
HEMATOLOGY / HEMOPHILIA
EMOCLOT / HUMACLOT / PLASMACLOT / EMOWIL / KLOTT*/ KOĀTE***
Factor VIII/Von Willebrand Factor concentrate
NUWIQ**
Recombinant Factor VIII
WILFACTIN**
Von Willebrand Factor concentrate
AIMAFIX / KEDRIFIX / IXED*
Factor IX concentrate
EMOSINT
DDAVP Desmopressin
IMMUNOLOGY / NEUROLOGY
Ig VENA / HUMAGLOBIN Liquid / KEDRIGAMMA / VENITAL*
Standard i.v. Immunoglobulin 5%
GAMMAKED***
Standard i.v. Immunoglobulin 10%
NAXIGLO / KEYCUTE*
Standard s.c. Immunoglobulin
MOTHER AND CHILD HEALTH
RhoGAM / ImmunoRHO / KeyRho / MICRhoGAM
Anti-D i.m. Immunoglobulin
IMMUNOHBs 180 IU
Anti-Hepatits B i.m. Immunoglobulin
INTENSIVE CARE & TRANSPLANTATION
UMAN ALBUMIN / UMAN SERUM / KALBI / HUMAN ALBUMIN / KEDRIALB / ALBITAL* / KEDBUMIN*** / ALBUKED*** / ALBUMINA LFB**
Human Albumin solution
KEDRAB***
Human Rabies Immunoglobulin
VENBIG / KEYVENB
Anti-Hepatitis B i.v. Immunoglobulin
IMMUNOHBs / UMAN BIG / KEDHBs*
Anti-Hepatits B i.m. Immunoglobulin
TETANUS GAMMA / TETIG
Anti-Tetanus i.m. Immunoglobulin
UMAN COMPLEX / KEDCOM*
PRONATIV**
Prothrombin Complex concentrate
AT III KEDRION / ATKED*
Antithrombin concentrate
KOLFIB / SILKETAL*
Fibrin sealant
K FLEBO
Potassium aspartate
TRANSFUSION MEDICINE
CERUS INTERCEPT**
Plasma and platelets pathogen inactivation
PLASMASAFE / PLASMAGRADE*
Pharmaceutical grade plasma
*Products for the Italian Self-Sufficiency Program
**Products in license
***Products only available for the US market
As of March 2020.
Orphan Drugs
Kedrion Human Plasminogen: a sterile human plasma derived plasminogen preparation in the pharmaceutical form of an eye drop solution for the treatment of Ligneous Conjunctivitis (currently under development product).
At the moment the product obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). The clinical trial is still ongoing for the Marketing Authorization approval in the USA and in Europe (EU).
